Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

Emtricitabine And Tenofovir Alafenamide · Descovy

Small molecule · Inhibitor of HIV-1 reverse transcriptase · developed by Gilead Sciences

Approved FDA, Apr 2016
GILD Developer
5 Registered trials

What is Emtricitabine And Tenofovir Alafenamide?

Emtricitabine and tenofovir alafenamide is a fixed-dose combination of two nucleoside analog reverse transcriptase inhibitors. Emtricitabine and tenofovir compete with natural deoxyribonucleosides for incorporation into the growing viral DNA chain, causing early chain termination and blocking HIV-1 reverse transcription. It is studied in HIV-1 infection, HIV-1 pre-exposure prophylaxis, and chronic kidney disease.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Descovy
Drug type
Small molecule
Targets
HIV-1 reverse transcriptase
Mechanism
Inhibitor of HIV-1 reverse transcriptase
Pathways
HIV-1 reverse transcription, viral DNA chain elongation
Therapy area
Infectious disease, Renal & urology
Developer
Gilead Sciences Inc (GILD)
FDA status
Approved as Descovy (April 4, 2016), NDA208215 · FDA label

✅ FDA-approved uses

From the indications section of the FDA label (version of Jul 7, 2026). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06337032 Phase 4 HIV-1-infection Recruiting GILD
NCT04925752 Phase 3 Pre-Exposure Prophylaxis of HIV Infection Active not recruiting GILD
NCT02842086 Phase 3 Pre-Exposure Prophylaxis of HIV-1 Infection Terminated GILD
NCT07812571 N/A Tenofovir Not yet recruiting GILD
NCT07473778 N/A HIV Infections Recruiting GILD

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Chronic Kidney DieaseHIV InfectionsHIV-1-infectionKidney FailurePharmacokineticsPre-Exposure Prophylaxis of HIV InfectionTenofovirTenofovir Alafenamide FumaratePre-Exposure Prophylaxis of HIV-1 Infection

More from Gilead Sciences

Axicabtagene Ciloleucel FDA approved Bictegravir FDA approved Brexucabtagene Autoleucel FDA approved Bulevirtide FDA approved Cobicistat FDA approved Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide FDA approved Emtricitabine/Tenofovir Disoproxil FDA approved Lenacapavir FDA approved Remdesivir FDA approved Sacituzumab Govitecan FDA approved Seladelpar FDA approved Tenofovir Disoproxil FDA approved

Sources

Updated Oct 11, 2026. Something wrong or missing? Report it on the GILD page.

Follow GILD, the company behind Emtricitabine And Tenofovir Alafenamide

See GILD's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

GILD catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.